HEAL DSpace

Antiphospholipid antibodies: Laboratory and pathogenetic aspects

Αποθετήριο DSpace/Manakin

Εμφάνιση απλής εγγραφής

dc.contributor.author Vlachoyiannopoulos, PG en
dc.contributor.author Samarkos, M en
dc.contributor.author Sikara, M en
dc.contributor.author Tsiligros, P en
dc.date.accessioned 2014-03-01T11:46:17Z
dc.date.available 2014-03-01T11:46:17Z
dc.date.issued 2007 en
dc.identifier.issn 1040-8363 en
dc.identifier.uri https://dspace.lib.ntua.gr/xmlui/handle/123456789/37770
dc.subject activated protein C resistance en
dc.subject anticardiolipin antibodies en
dc.subject antiphospholipid antibodies en
dc.subject antiphospholipid syndrome en
dc.subject CD40 en
dc.subject endothelial cells en
dc.subject fibrinolysis en
dc.subject hypercoagulable state en
dc.subject lupus coagulation inhibitor en
dc.subject systemic lupus erythematosus en
dc.subject thrombophilia en
dc.subject.classification Medical Laboratory Technology en
dc.subject.other SYSTEMIC-LUPUS-ERYTHEMATOSUS en
dc.subject.other ACTIVATED PROTEIN-C en
dc.subject.other KAOLIN CLOTTING TIME en
dc.subject.other ANTI-BETA(2)-GLYCOPROTEIN I ANTIBODIES en
dc.subject.other MONOCLONAL ANTICARDIOLIPIN ANTIBODIES en
dc.subject.other ANTI-PROTHROMBIN ANTIBODIES en
dc.subject.other PARTIAL THROMBOPLASTIN TIME en
dc.subject.other VIPER VENOM TIME en
dc.subject.other HUMAN ENDOTHELIAL-CELLS en
dc.subject.other FACTOR-V-LEIDEN en
dc.title Antiphospholipid antibodies: Laboratory and pathogenetic aspects en
heal.type other en
heal.language English en
heal.publicationDate 2007 en
heal.abstract Antiphospholipid antibodies ( aPL) constitute a heterogeneous group of autoantibodies that share the ability to bind phospholipids ( PL) alone, protein- PL complexes, or PL-binding proteins. They have been detected in isolation, in association with autoimmune diseases such as systemic lupus erythematosus ( SLE), and during the course of different infections. aPL have been associated with an array of clinical manifestations in virtually every organ, although deep vein and arterial thrombosis as well as pregnancy morbidity are predominant. The co-occurrence of these clinical findings with aPL constitutes the so-called antiphospholipid syndrome ( APS). aPL can be detected by immunological methods [ e. g., anticardiolipin antibodies ( aCL)] or by functional methods that exploit the effect of aPL on blood coagulation [ lupus anticoagulant ( LA)]. Since aPL are heterogeneous, numerous immunological and coagulation assays have been developed. These assays have not been fully standardized, and, therefore, problems such as high interlaboratory variation are relatively frequent. Recently, recommendations have been published regarding LA and aCL testing. Not all aPL are pathogenic. However, when they are not associated with infections, they have a role in the pathogenesis of APS. Clinical and experimental data have shown that aPL exert their pathogenic activity by interfering with the function of coagulation factors, such as thrombin and factors X, XI and XII, and with the function of anticoagulant proteins of the protein C system. In addition, aPL interaction with platelets and endothelial cells induces a pro- adhesive activated phenotype. en
heal.publisher TAYLOR & FRANCIS INC en
heal.journalName CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES en
dc.identifier.isi ISI:000247564000003 en
dc.identifier.volume 44 en
dc.identifier.issue 3 en
dc.identifier.spage 271 en
dc.identifier.epage 338 en


Αρχεία σε αυτό το τεκμήριο

Αρχεία Μέγεθος Μορφότυπο Προβολή

Δεν υπάρχουν αρχεία που σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στην ακόλουθη συλλογή(ές)

Εμφάνιση απλής εγγραφής